Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour modelResearch in context

Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour modelResearch in context

Summary: Background: mRNA-based cancer vaccines show promise in triggering antitumour immune responses. To combine them with existing immunotherapies, the intratumoral immune microenvironment needs to be deeply characterised. Here, we test nanostructured lipid carriers (NLCs), the so-called Lipidot...

Full description

Saved in:
Bibliographic Details
Main Authors: Carole Fournier, Marion Mercey-Ressejac, Valentin Derangère, Amal Al Kadi, David Rageot, Christine Charrat, Alexis Leroy, Julien Vollaire, Véronique Josserand, Marie Escudé, Séverine Escaich, François Ghiringhelli, Thomas Decaens, Fabrice P. Navarro, Evelyne Jouvin-Marche, Patrice N. Marche
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:EBioMedicine
Subjects:
mRNA vaccine
Immune checkpoint inhibitor
Cancer
T cells
Innate immunity
Memory immunity
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424005796
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352396424005796

Similar Items